{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T18:05:51Z","timestamp":1777485951989,"version":"3.51.4"},"reference-count":125,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To analyses real-world safety data of mRNA COVID-19 vaccines within the European Economic Area (EEA), using Individual Case Safety Reports (ICSR), and to evaluate the variability in safety profiles between different vaccine versions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We utilized EudraVigilance data from 1 January 2020, to 31 December 2023, focusing on Moderna (Spikevax) and Pfizer\/BioNTech (Comirnaty) vaccines against COVID-19. We performed descriptive statistics, co-occurrence analysis, and correspondence analysis to identify patterns and clusters of adverse events following immunization (AEFI).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We retrieved 993,199 ICSR (Moderna: 394,484; Pfizer: 605,794), with most reports related to women patients (69%) and non-healthcare professionals (65%). A total of 10,804 distinct AEFI terms were described across the retrieved ICSR, with a cumulative occurrence frequency of 3,558,219 (Moderna: 1,555,638; Pfizer: 2,031,828). The most prominent serious clusters included headache, fatigue, pyrexia, myalgia, arthralgia, malaise, nausea, and chills, which frequently co-occurred with vaccination failure. Specific AEFI like fever, chills, malaise, arthralgia, injection site pain, inflammation, and warmth were more often linked to Moderna, while Pfizer was more commonly associated with vaccination failure, menstrual disorders (heavy menstrual bleeding and dysmenorrhea), and hypoesthesia. In older adults, serious clusters included confusional states, cerebrovascular accidents, and myocardial infarctions, while myocarditis and pericarditis were noted in younger males. Although rare, serious systemic AEFI, like anaphylactic reactions, were identified but require further causality evaluation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The overall safety of mRNA COVID-19 vaccines for mass vaccination is supported, but continuous pharmacovigilance remains essential. Identified clusters of AEFI, particularly serious and systemic ones, although rare and potentially influenced by other underlying causes, underscore the need for continuous monitoring and further epidemiological investigations to explore potential causal relationships.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2025.1501921","type":"journal-article","created":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T06:50:57Z","timestamp":1739947857000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Network analysis of adverse event patterns following immunization with mRNA COVID-19 vaccines: real-world data from the European pharmacovigilance database EudraVigilance"],"prefix":"10.3389","volume":"12","author":[{"given":"Renato","family":"Ferreira-da-Silva","sequence":"first","affiliation":[]},{"given":"Mariana Fernandes","family":"Lobo","sequence":"additional","affiliation":[]},{"given":"Ana Margarida","family":"Pereira","sequence":"additional","affiliation":[]},{"given":"Manuela","family":"Morato","sequence":"additional","affiliation":[]},{"given":"Jorge Junqueira","family":"Pol\u00f3nia","sequence":"additional","affiliation":[]},{"given":"In\u00eas","family":"Ribeiro-Vaz","sequence":"additional","affiliation":[]}],"member":"1965","published-online":{"date-parts":[[2025,2,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18836-4","article-title":"Inference of person-to-person transmission of COVID-19 reveals hidden super-spreading events during the early outbreak phase.","volume":"11","author":"Wang","year":"2020","journal-title":"Nat Commun"},{"key":"B2","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/s41586-022-05522-2","article-title":"The WHO estimates of excess mortality associated with the COVID-19 pandemic.","volume":"613","author":"Msemburi","year":"2023","journal-title":"Nature"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1016\/j.vaccine.2023.02.008","article-title":"Protective effect of COVID-19 vaccination against long COVID syndrome: A systematic review and meta-analysis.","volume":"41","author":"Watanabe","year":"2023","journal-title":"Vaccine"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1038\/s41591-024-02962-3","article-title":"Correlates of protection against symptomatic SARS-CoV-2 in vaccinated children.","volume":"30","author":"Zhong","year":"2024","journal-title":"Nat Med."},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.Cd015477","article-title":"Efficacy and safety of COVID-19 vaccines.","volume":"12","author":"Gra\u00f1a","year":"2022","journal-title":"Cochr Datab Syst Rev"},{"key":"B6","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/s41562-021-01122-8","article-title":"A global database of COVID-19 vaccinations.","volume":"5","author":"Mathieu","year":"2021","journal-title":"Nat Hum Behav."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2508","DOI":"10.1016\/j.csbj.2021.04.061","article-title":"An overview of current COVID-19 vaccine platforms.","volume":"19","author":"Nagy","year":"2021","journal-title":"Comput Struct Biotechnol J"},{"key":"B8","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines \u2014 a new era in vaccinology.","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"B9","year":"2024","journal-title":"COVID-19-Medicines."},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9020147","article-title":"SARS-CoV-2 mRNA vaccines: Immunological mechanism and beyond.","volume":"9","author":"Bettini","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine.","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine.","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/s41591-021-01230-y","article-title":"Looking beyond COVID-19 vaccine phase 3 trials.","volume":"27","author":"Kim","year":"2021","journal-title":"Nat Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"4348","DOI":"10.1016\/j.vaccine.2022.05.067","article-title":"Benefit-risk evaluation of COVID-19 vaccination in special population groups of interest.","volume":"40","author":"Moss","year":"2022","journal-title":"Vaccine"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.101965","article-title":"Vaccines and therapeutics for immunocompromised patients with COVID-19.","volume":"59","author":"Shoham","year":"2023","journal-title":"eClinicalMedicine."},{"key":"B16","doi-asserted-by":"publisher","first-page":"e594","DOI":"10.1016\/S2589-7500(23)00093-6","article-title":"Effect of COVID-19 vaccination and booster on maternal&#x2013;fetal outcomes: A retrospective cohort study.","volume":"5","author":"Piekos","year":"2023","journal-title":"Lancet Digital Health"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1002\/jcph.2120","article-title":"Anaphylaxis and related events following COVID-19 vaccination: A systematic review.","volume":"62","author":"Paul","year":"2022","journal-title":"J Clin Pharmacol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1007\/s00415-024-12186-7","article-title":"Guillain-Barr\u00e9 syndrome and COVID-19 vaccination: A systematic review and meta-analysis.","volume":"271","author":"Censi","year":"2024","journal-title":"J Neurol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-023-00681-3","article-title":"Systematic review and meta-analysis of myocarditis and pericarditis in adolescents following COVID-19 BNT162b2 vaccination.","volume":"8","author":"Katoto","year":"2023","journal-title":"NPJ Vaccines"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1177\/10760296211048815","article-title":"COVID-19 vaccine-associated Thrombosis With Thrombocytopenia Syndrome (TTS): A systematic review and post hoc analysis.","volume":"27","author":"Hafeez","year":"2021","journal-title":"Clin Appl Thromb Hemost"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/eci.13947","article-title":"COVID-19 vaccine induced myocarditis in young males: A systematic review.","volume":"53","author":"Knudsen","year":"2023","journal-title":"Eur J Clin Invest"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcha.2023.101280","article-title":"COVID-19 vaccine-associated myocarditis: Analysis of the suspected cases reported to the EudraVigilance and a systematic review of the published literature.","volume":"49","author":"Jaiswal","year":"2023","journal-title":"IJC Heart Vasc"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.874687","article-title":"COVID-19 vaccination in pediatric population: A necessity or obstruction to the protection of the right to health? Biojuridical Perspective.","volume":"10","author":"Bilotta","year":"2022","journal-title":"Front Public Health."},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10020233","article-title":"Gender differences in adverse events following the Pfizer-BioNTech COVID-19 Vaccine.","volume":"10","author":"Green","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e630","DOI":"10.1093\/cid\/ciac103","article-title":"Prospective evaluation of coronavirus disease 2019 (COVID-19) vaccine responses across a broad spectrum of immuno compromising conditions: The COVID-19 vaccination in the immunocompromised study (COVICS).","volume":"75","author":"Haidar","year":"2022","journal-title":"Clin Infect Dis"},{"key":"B26","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1111\/1756-185x.14279","article-title":"Early experience of COVID-19 vaccine-related adverse events among adolescents and young adults with rheumatic diseases: A single-center study.","volume":"25","author":"Haslak","year":"2022","journal-title":"Int J Rheum Dis"},{"key":"B27","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s40121-022-00742-5","article-title":"Safety profiles of mRNA COVID-19 vaccines using World Health Organization Global Scale Database (VigiBase): A latent class analysis.","volume":"12","author":"Lee","year":"2023","journal-title":"Infect Dis Ther"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1111\/jgs.17814","article-title":"Delirium after COVID-19 vaccination in nursing home residents: A case series.","volume":"70","author":"Mak","year":"2022","journal-title":"J Am Geriatr Soc"},{"key":"B29","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/j.jamda.2023.04.003","article-title":"Risk of adverse events and delirium after COVID-19 vaccination in patients living with dementia.","volume":"24","author":"Cheung","year":"2023","journal-title":"J Am Med Direct Assoc."},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.909412","article-title":"COVID-19 vaccine-associated transient global amnesia: A disproportionality analysis of the WHO safety database.","volume":"13","author":"Merino","year":"2022","journal-title":"Front Pharmacol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11910-022-01247-x","article-title":"Neurological complications following COVID-19 vaccination.","volume":"23","author":"Chatterjee","year":"2023","journal-title":"Curr Neurol Neurosci Rep"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.23779","article-title":"Case series of three neurological side effects in younger-aged individuals after Pfizer\u2019s mRNA vaccine.","volume":"14","author":"Dinetz","year":"2022","journal-title":"Cureus"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fdsfr.2024.1338466","article-title":"Menstrual disorders following COVID-19 vaccination: A review using a systematic search. Systematic Review.","volume":"4","author":"Smaardijk","year":"2024","journal-title":"Front Drug Saf Regul."},{"key":"B34","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.jiph.2023.02.019","article-title":"COVID-19 vaccination and menstrual disorders among women: Findings from a meta-analysis study.","volume":"16","author":"Al Kadri","year":"2023","journal-title":"J Infect Public Health"},{"key":"B35","year":"2024","journal-title":"EudraVigilance - European Database of Suspected Adverse Reactions Related to Medicines: User Manual for Online Access via the Adrreports.eu Portal."},{"key":"B36","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","article-title":"The medical dictionary for regulatory activities (MedDRA).","volume":"20","author":"Brown","year":"1999","journal-title":"Drug Saf"},{"key":"B37","year":"2024","journal-title":"ICH E2D Post-Approval Safety Data Management - Scientific Guideline."},{"key":"B38","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1136\/bmj.39335.541782.AD","article-title":"Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies.","volume":"335","author":"von Elm","year":"2007","journal-title":"BMJ"},{"key":"B39","year":"2023","journal-title":"ENCePP Guide on Methodological Standards in Pharmacoepidemiology."},{"key":"B40","doi-asserted-by":"publisher","first-page":"57054","DOI":"10.1007\/s11356-022-21553-8","article-title":"Differences in global scientific production between new mRNA and conventional vaccines against COVID-19.","volume":"29","author":"Ruiz-Fresneda","year":"2022","journal-title":"Environ Sci Pollut Res Int"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2022.104047","article-title":"A probabilistic model for co-occurrence analysis in bibliometrics.","volume":"128","author":"Zhou","year":"2022","journal-title":"J Biomed Inform"},{"key":"B42","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1111\/j.1466-8238.2012.00789.x","article-title":"A probabilistic model for analysing species co-occurrence.","volume":"22","author":"Veech","year":"2013","journal-title":"Glob Ecol Biogeogr"},{"key":"B43","article-title":"Practical Guide to Principal Component Methods in R: PCA, M (CA), FAMD, MFA, HCPC, Factoextra","author":"Kassambara","year":"2017"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.790740","article-title":"Association of Direct Oral Anticoagulants (DOACs) and Warfarin With Haemorrhagic Risk by applying correspondence analysis to data from the Italian pharmacovigilance database - A case study.","volume":"12","author":"Gaio","year":"2021","journal-title":"Front Pharmacol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"552","DOI":"10.7326\/m20-8060","article-title":"Public health COVID-19 vaccination strategy to maximize the health gains for every single vaccine dose.","volume":"174","author":"Barnabas","year":"2021","journal-title":"Ann Intern Med"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abf1374","article-title":"Vaccine optimization for COVID-19: Who to vaccinate first?","volume":"7","author":"Matrajt","year":"2020","journal-title":"Sci Adv"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.43955","article-title":"Frequency of adverse events in the placebo arms of COVID-19 vaccine trials: A systematic review and meta-analysis.","volume":"5","author":"Haas","year":"2022","journal-title":"JAMA Netw Open"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9080939","article-title":"Nervous and muscular adverse events after COVID-19 vaccination: A systematic review and meta-analysis of clinical trials.","volume":"9","author":"Chen","year":"2021","journal-title":"Vaccines (Basel)."},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1186\/s40249-021-00915-3","article-title":"Effectiveness and safety of SARS-CoV-2 vaccine in real-world studies: A systematic review and meta-analysis.","volume":"10","author":"Liu","year":"2021","journal-title":"Infect Dis Poverty"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9050467","article-title":"Efficacy and safety of COVID-19 vaccines: A systematic review and meta-analysis of randomized clinical trials.","volume":"9","author":"Pormohammad","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.21376","article-title":"Analysis of neurological adverse events reported in VigiBase from COVID-19 vaccines.","volume":"14","author":"Dutta","year":"2022","journal-title":"Cureus"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3390\/life11030249","article-title":"Self-reported real-world safety and reactogenicity of COVID-19 vaccines: A vaccine recipient survey.","volume":"11","author":"Mathioudakis","year":"2021","journal-title":"Life (Basel)"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.714170","article-title":"Efficacy, immunogenicity and safety of COVID-19 vaccines: A systematic review and meta-analysis.","volume":"12","author":"Sharif","year":"2021","journal-title":"Front Immunol"},{"key":"B54","year":"2017","journal-title":"Common Terminology Criteria for Adverse Events (CTCAE)."},{"key":"B55","doi-asserted-by":"publisher","first-page":"3636","DOI":"10.1111\/jocd.15261","article-title":"Cutaneous adverse reactions following COVID-19 vaccinations: A systematic review and meta-analysis.","volume":"21","author":"Shafie\u2019ei","year":"2022","journal-title":"J Cosmet Dermatol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1186\/s43162-022-00129-5","article-title":"Immune-mediated adverse events post-COVID vaccination and types of vaccines: A systematic review and meta-analysis.","volume":"34","author":"ElSawi","year":"2022","journal-title":"Egypt J Intern Med"},{"key":"B57","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1007\/s12026-023-09357-5","article-title":"COVID-19 vaccines adverse events: Potential molecular mechanisms.","volume":"71","author":"Lamprinou","year":"2023","journal-title":"Immunol Res"},{"key":"B58","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.cmi.2021.09.018","article-title":"Real-world safety data for the Pfizer BNT162b2 SARS-CoV-2 vaccine: Historical cohort study.","volume":"28","author":"Shasha","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"B59","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1002\/mus.27251","article-title":"Post COVID-19 vaccine small fiber neuropathy.","volume":"64","author":"Waheed","year":"2021","journal-title":"Muscle Nerve"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.amsu.2021.102819","article-title":"Combined subacromial-subdeltoid bursitis and supraspinatus tear following a COVID-19 vaccination: A case report.","volume":"69","author":"Boonsri","year":"2021","journal-title":"Ann Med Surg (Lond)"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9050502","article-title":"The incidence and severity of post-vaccination reactions after vaccination against COVID-19.","volume":"9","author":"J\u00ea\u015bkowiak","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"B62","first-page":"217","article-title":"Shoulder pain and injury after COVID-19 vaccination.","volume":"95","author":"Sahu","year":"2022","journal-title":"Yale J Biol Med"},{"key":"B63","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1177\/0976500X221147748","article-title":"Delayed extensive local reaction to the mRNA-1273 vaccine against SARS-CoV-2: A case report.","volume":"13","author":"Ferreira-da-Silva","year":"2022","journal-title":"J Pharmacol Pharmacother"},{"key":"B64","doi-asserted-by":"publisher","first-page":"3631","DOI":"10.1016\/j.radcr.2021.08.019","article-title":"Shoulder injury related to vaccine administration (SIRVA) following mRNA COVID-19 vaccination: Report of 2 cases of subacromial-subdeltoid bursitis.","volume":"16","author":"Honarmand","year":"2021","journal-title":"Radiol Case Rep"},{"key":"B65","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1111\/papr.13177","article-title":"Post-COVID-19 vaccination arm pain diagnosed as complex regional pain syndrome: A case report.","volume":"23","author":"Cho","year":"2023","journal-title":"Pain Pract"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.40364","article-title":"Analysis of COVID-19 vaccine type and adverse effects following vaccination.","volume":"4","author":"Beatty","year":"2021","journal-title":"JAMA Network Open"},{"key":"B67","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1111\/all.14774","article-title":"Other excipients than PEG might cause serious hypersensitivity reactions in COVID-19 vaccines.","volume":"76","author":"Borgsteede","year":"2021","journal-title":"Allergy"},{"key":"B68","doi-asserted-by":"publisher","first-page":"339","DOI":"10.33160\/yam.2021.11.003","article-title":"Physical characteristics of injection site pain after COVID-19 mRNA BNT162b2 vaccination.","volume":"64","author":"Tomita","year":"2021","journal-title":"Yonago Acta Med"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2023.106401","article-title":"A retrospective case-control study on menstrual cycle changes following COVID-19 vaccination and disease.","volume":"26","author":"Alvergne","year":"2023","journal-title":"iScience."},{"key":"B70","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.4314\/ejhs.v32i6.4","article-title":"Effect of the COVID-19 vaccine on the menstrual cycle among females in Saudi Arabia.","volume":"32","author":"Qashqari","year":"2022","journal-title":"Ethiop J Health Sci"},{"key":"B71","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1097\/aog.0000000000004695","article-title":"Association between menstrual cycle length and coronavirus disease 2019 (COVID-19) vaccination: A U.S. Cohort.","volume":"139","author":"Edelman","year":"2022","journal-title":"Obstet Gynecol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1515\/med-2022-0452","article-title":"Evaluation of menstrual irregularities after COVID-19 vaccination: Results of the MECOVAC survey.","volume":"17","author":"Lagan\u00e0","year":"2022","journal-title":"Open Med"},{"key":"B73","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1002\/ijgo.14356","article-title":"The effect of BNT162b2 SARS-CoV-2 mRNA vaccine on menstrual cycle symptoms in healthy women.","volume":"160","author":"Lessans","year":"2023","journal-title":"Int J Gynaecol Obstet"},{"key":"B74","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1001\/jama.2023.8658","article-title":"COVID-19 vaccine and health care visits for menstrual changes.","volume":"329","author":"Harris","year":"2023","journal-title":"JAMA"},{"key":"B75","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/j.vaccine.2022.11.068","article-title":"Menstrual disturbances in 12- to 15-year-old girls after one dose of COVID-19 Comirnaty vaccine: Population-based cohort study in Norway.","volume":"41","author":"Caspersen","year":"2023","journal-title":"Vaccine"},{"key":"B76","doi-asserted-by":"publisher","first-page":"A486","DOI":"10.1016\/j.autrev.2011.11.023","article-title":"Immunology and the menstrual cycle.","volume":"11","author":"Oertelt-Prigione","year":"2012","journal-title":"Autoimmun Rev"},{"key":"B77","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1111\/irv.12509","article-title":"Rapid changes in serum cytokines and chemokines in response to inactivated influenza vaccination.","volume":"12","author":"Talaat","year":"2018","journal-title":"Influenza Other Respir Viruses"},{"key":"B78","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.pvr.2018.02.002","article-title":"No association between HPV vaccine and reported post-vaccination symptoms in Japanese young women: Results of the Nagoya study.","volume":"5","author":"Suzuki","year":"2018","journal-title":"Papillomavirus Res"},{"key":"B79","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s00281-018-0726-5","article-title":"Sex differences in vaccine-induced humoral immunity.","volume":"41","author":"Fischinger","year":"2019","journal-title":"Semin Immunopathol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"e667","DOI":"10.1016\/s2589-7500(22)00125-x","article-title":"Menstrual irregularities and vaginal bleeding after COVID-19 vaccination reported to v-safe active surveillance, USA in December, 2020-January, 2022: An observational cohort study.","volume":"4","author":"Wong","year":"2022","journal-title":"Lancet Digit Health"},{"key":"B81","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s40264-023-01304-5","article-title":"Safety of COVID-19 vaccines among the paediatric population: Analysis of the European Surveillance Systems and Pivotal Clinical Trials.","volume":"46","author":"Ahmadizar","year":"2023","journal-title":"Drug Saf"},{"key":"B82","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/s1473-3099(22)00054-8","article-title":"Safety of mRNA vaccines administered during the initial 6 months of the US COVID-19 vaccination programme: An observational study of reports to the Vaccine Adverse Event Reporting System and v-safe.","volume":"22","author":"Rosenblum","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"B83","doi-asserted-by":"publisher","first-page":"4644","DOI":"10.1002\/jmv.27940","article-title":"Safety and efficacy of COVID-19 vaccines in children and adolescents: A systematic review of randomized controlled trials.","volume":"94","author":"Tian","year":"2022","journal-title":"J Med Virol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-023-02924-5","article-title":"Reactogenicity and safety of COVID-19 primary immunisation and booster vaccination regimens: A comparative observational cohort study.","volume":"21","author":"Warkentin","year":"2023","journal-title":"BMC Med"},{"key":"B85","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.vaccine.2021.12.001","article-title":"Acute unsolicited adverse events following BNT162b2 vaccine in Saudi Arabia, a real-world data.","volume":"40","author":"Almohaya","year":"2022","journal-title":"Vaccine"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10122115","article-title":"Vaccine vigilance system: Considerations on the effectiveness of vigilance data use in COVID-19 vaccination.","volume":"10","author":"Araja","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"B87","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1111\/fcp.12866","article-title":"Drug-induced radiation recall reactions and non-anticancer drugs: A descriptive analysis from VigiBase\u00a7.","volume":"37","author":"Aubin-Beale","year":"2023","journal-title":"Fundam Clin Pharmacol"},{"key":"B88","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1002\/jmv.27424","article-title":"Comparative safety of mRNA COVID-19 vaccines to influenza vaccines: A pharmacovigilance analysis using WHO international database.","volume":"94","author":"Kim","year":"2022","journal-title":"J Med Virol"},{"key":"B89","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1016\/j.vaccine.2023.02.067","article-title":"Anaphylaxis rates following mRNA COVID-19 vaccination in children and adolescents: Analysis of data reported to EudraVigilance.","volume":"41","author":"Maltezou","year":"2023","journal-title":"Vaccine"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines11030613","article-title":"Anaphylactic reactions to COVID-19 vaccines: An updated assessment based on pharmacovigilance data.","volume":"11","author":"Boufidou","year":"2023","journal-title":"Vaccines (Basel)."},{"key":"B91","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jaci.2012.04.003","article-title":"Adverse reactions to vaccines practice parameter 2012 update.","volume":"130","author":"Kelso","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"B92","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines9030221","article-title":"Allergic reactions to current available COVID-19 vaccinations: Pathophysiology, causality, and therapeutic considerations.","volume":"9","author":"Kounis","year":"2021","journal-title":"Vaccines"},{"key":"B93","doi-asserted-by":"publisher","first-page":"3307","DOI":"10.1111\/all.14794","article-title":"Allergenic components of the mRNA-1273 vaccine for COVID-19: Possible involvement of polyethylene glycol and IgG-mediated complement activation.","volume":"76","author":"Klimek","year":"2021","journal-title":"Allergy"},{"key":"B94","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.alit.2021.04.003","article-title":"Allergy to COVID-19 vaccines: A current update.","volume":"70","author":"Cabanillas","year":"2021","journal-title":"Allergol Int"},{"key":"B95","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jacig.2022.10.003","article-title":"The conundrum of COVID-19 mRNA vaccine-induced anaphylaxis.","volume":"2","author":"Khalid","year":"2023","journal-title":"J Allergy Clin Immunol Glob"},{"key":"B96","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1001\/jamainternmed.2021.8515","article-title":"Risk of second allergic reaction to SARS-CoV-2 vaccines: A systematic review and meta-analysis.","volume":"182","author":"Chu","year":"2022","journal-title":"JAMA Intern Med"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.25524","article-title":"Assessment of allergic and anaphylactic reactions to mRNA COVID-19 vaccines with confirmatory testing in a US regional health system.","volume":"4","author":"Warren","year":"2021","journal-title":"JAMA Netw Open"},{"key":"B98","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1016\/j.jaci.2021.04.002","article-title":"Potential mechanisms of anaphylaxis to COVID-19 mRNA vaccines.","volume":"147","author":"Risma","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B99","doi-asserted-by":"publisher","first-page":"46","DOI":"10.15585\/mmwr.mm7002e1","article-title":"Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 Vaccine \u2014 United States, December 14\u201323.","volume":"70","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep."},{"key":"B100","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s11882-023-01065-2","article-title":"mRNA COVID-19 vaccine anaphylaxis: Epidemiology, risk factors, and evaluation.","volume":"23","author":"Jaggers","year":"2023","journal-title":"Curr Allergy Asthma Rep"},{"key":"B101","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.vaccine.2021.11.066","article-title":"Anaphylaxis rates associated with COVID-19 vaccines are comparable to those of other vaccines.","volume":"40","author":"Maltezou","year":"2022","journal-title":"Vaccine"},{"key":"B102","doi-asserted-by":"publisher","first-page":"2562","DOI":"10.1016\/j.jaip.2021.04.025","article-title":"Ascertainment bias in anaphylaxis safety data of COVID-19 vaccines.","volume":"9","author":"Hourihane","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1002\/hsr2.787","article-title":"Anaphylaxis and allergic reactions to COVID-19 vaccines: A narrative review of characteristics and potential obstacles on achieving herd immunity.","volume":"5","author":"Mahdiabadi","year":"2022","journal-title":"Health Sci Rep"},{"key":"B104","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.jaci.2017.12.971","article-title":"Vaccine-associated hypersensitivity.","volume":"141","author":"McNeil","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10071067","article-title":"Rare adverse events associated with BNT162b2 mRNA vaccine (Pfizer-BioNTech): A review of large-scale, controlled surveillance studies.","volume":"10","author":"Yong","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"B106","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1001\/jamacardio.2022.0583","article-title":"SARS-CoV-2 vaccination and myocarditis in a Nordic cohort study of 23 million residents.","volume":"7","author":"Karlstad","year":"2022","journal-title":"JAMA Cardiol"},{"key":"B107","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1001\/jama.2021.15072","article-title":"Surveillance for adverse events after COVID-19 mRNA vaccination.","volume":"326","author":"Klein","year":"2021","journal-title":"JAMA"},{"key":"B108","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.1056\/NEJMoa2109730","article-title":"Myocarditis after BNT162b2 mRNA vaccine against COVID-19 in Israel.","volume":"385","author":"Mevorach","year":"2021","journal-title":"N Engl J Med"},{"key":"B109","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41569-021-00662-w","article-title":"Myocarditis after COVID-19 mRNA vaccination: Clinical observations and potential mechanisms.","volume":"19","author":"Heymans","year":"2022","journal-title":"Nat Rev Cardiol"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-068665","article-title":"SARS-CoV-2 vaccination and myocarditis or myopericarditis: Population based cohort study.","volume":"375","author":"Husby","year":"2021","journal-title":"BMJ"},{"key":"B111","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1038\/s41591-021-01630-0","article-title":"Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection.","volume":"28","author":"Patone","year":"2022","journal-title":"Nat Med"},{"key":"B112","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1161\/circresaha.118.311378","article-title":"Mechanisms of vascular aging.","volume":"123","author":"Ungvari","year":"2018","journal-title":"Circ Res"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.700014","article-title":"Age and gender disparities in adverse events following COVID-19 vaccination: Real-world evidence based on big data for risk management.","volume":"8","author":"Xiong","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2021.102742","article-title":"Cardiovascular, neurological, and pulmonary events following vaccination with the BNT162b2, ChAdOx1 nCoV-19, and Ad26.COV2.S vaccines: An analysis of European data.","volume":"125","author":"Cari","year":"2021","journal-title":"J Autoimmun"},{"key":"B115","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1056\/NEJMe2106315","article-title":"SARS-CoV-2 vaccine-induced immune thrombotic thrombocytopenia.","volume":"384","author":"Cines","year":"2021","journal-title":"N Engl J Med"},{"key":"B116","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s11739-021-02685-0","article-title":"Deep vein thrombosis (DVT) occurring shortly after the second dose of mRNA SARS-CoV-2 vaccine.","volume":"16","author":"Carli","year":"2021","journal-title":"Intern Emerg Med"},{"key":"B117","doi-asserted-by":"publisher","first-page":"3656","DOI":"10.1111\/ene.15029","article-title":"Post-SARS-CoV-2-vaccination cerebral venous sinus thrombosis: An analysis of cases notified to the European Medicines Agency.","volume":"28","author":"Krzywicka","year":"2021","journal-title":"Eur J Neurol"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2020.571416","article-title":"Aging, immunity, and COVID-19: How age influences the host immune response to coronavirus infections?","volume":"11","author":"Bajaj","year":"2020","journal-title":"Front Physiol"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.2507","article-title":"Safety and efficacy of COVID-19 vaccines: A systematic review and meta-analysis of controlled and randomized clinical trials.","volume":"34","author":"Beladiya","year":"2024","journal-title":"Rev Med Virol"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1126\/science.abf4063","article-title":"Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection.","volume":"371","author":"Dan","year":"2021","journal-title":"Science."},{"key":"B121","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1056\/NEJMoa2201570","article-title":"Protection by a fourth dose of BNT162b2 against Omicron in Israel.","volume":"386","author":"Bar-On","year":"2022","journal-title":"N Engl J Med"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10050796","article-title":"Quantitative and qualitative difference in antibody response against omicron and ancestral SARS-CoV-2 after third and fourth vaccination.","volume":"10","author":"Hein","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"B123","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1016\/s1473-3099(22)00409-1","article-title":"Duration of effectiveness of vaccination against COVID-19 caused by the omicron variant.","volume":"22","author":"Higdon","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijheh.2023.114224","article-title":"The dominance of co-circulating SARS-CoV-2 variants in wastewater.","volume":"253","author":"Pilapil","year":"2023","journal-title":"Int J Hyg Environ Health"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101624","article-title":"Impact of COVID-19 vaccination on the risk of developing long-COVID and on existing long-COVID symptoms: A systematic review.","volume":"53","author":"Notarte","year":"2022","journal-title":"EClinicalMedicine"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1501921\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T06:51:03Z","timestamp":1739947863000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1501921\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,19]]},"references-count":125,"alternative-id":["10.3389\/fmed.2025.1501921"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1501921","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,19]]},"article-number":"1501921"}}